October 13 JLM-BIOCITY Online Meeting on
“Synthetic Biology for Pharma and Therapeutics – Future Trends And What Is In It For You”

with Yaron Daniely, aMoon Investment Fund
Aryeh Batt -Precise Bio https://www.precise-bio.com/
Shlomzion Shen -Seevix https://www.seevix.com/
Irit Carmi-Levy -Aummune https://www.aummune.com/
Einat Zisman -Tissue Dynamics https://bioengineering.huji.ac.il/tissue-dynamics-0

Synthetic Biology is poised to deliver new solutions to global healthcare, agriculture, manufacturing, and environmental challenges; this emerging, exciting interdisciplinary area consists of redesigning biological organisms for useful purposes with the help of engineering techniques for making new abilities.

Reaching a record of $8 Billion investments in 2020 making Synthetic Biology the fastest growing area in Life Science! Projected to grow to USD 30.7 billion in 2026 from USD 9.5 billion in 2021.
First successes have been in medicine and pharma. Harnessing the natural power of enzymes or whole cells and using sugars as the feedstock for product manufacturing, would move us from a petroleum-based economy to a bio-based economy! Patients are benefiting from CAR technology, which engineers the immune cells of the patient to recognize and attack cancer cells.
Viruses or microbes are being genetically engineered to both detect and kill a particular pathogen, for example, the bacteria that causes cholera.

Synthetic Biology is a major priority area. We are launching a series of events in this exciting field, starting on Synthetic Biology applied to medicine & pharma.

The event is organized by JLM-BioCity & co-sponsored by Azrieli College of Engineering & AtoBe.

YARON DANIELY, Partner & Hd, aMoon Alpha.
Before aMoon, Yaron was President and CEO of Yissum, Hebrew University’s Technology Transfer Company, and Co-Chair of the Israel Technology Transfer Network (ITTN). Before Yissum, he spent 14 years as a senior executive and 10 years as CEO of private and NASDAQ Pharma and Biotech companies. Earned his Ph.D. in Biomedical Sciences at the NYU School of Medicine and served as a Visiting Fellow at the NIH.

ARYEH BATT, CEO & co-founder, PreciseBio
Over two decades of executive experience leading product management and development of innovative technology products and bringing them from R&D to marketing and sales. Was Vice President of Business and Director of Corporate R&D at Orbotech (NASDAQ: ORBK) and CTO, Vice President of Business Development, and Vice President of R&D at MangoDSP. A BSc in Physics and Electro-optics Engineering from the Jerusalem College of Technology.

Chief Scientist & VP R&D at Aummune Ltd, a biotech company focused on the development of personalized therapies for cancer. Prior to Aummune, served as a Project Director in BioLineRx. A drug development expert and an immunologist by training. Performed postdoctoral research at the Curie Institute. Ph.D. in Biochemistry & Molecular Biology from Hebrew University.

SHLOMZION SHEN, Seevix Medical
Over 20 years of experience in business dev and R&D management roles at life science startups and late-stage companies. Responsible for advancing products from early-stage research to late-stage development and licensing deals with strategic partners in the US, Europe, and Japan. Before Seevix, was CEO of MedAware Ltd., and CEO of Fluonic Inc. Ph.D. in Biology from Bar-Ilan University.

Einat Zisman, Tissue Dynamics
A versatile goal-oriented CEO with broad experience in building value via inception and seeding of start-ups, evaluating and commercializing technologies, generating creative financing vehicles, in-, and out- licensing, partnering, financing, and marketing early-stage intellectual property across multiple fields, focusing on biotech and Biomed. Formerly, CEO, FutuRX and CEO, Hadasit.